Overview

Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load

Status:
Not yet recruiting

Trial end date:
2026-02-28

Target enrollment:

Participant gender:

Summary

The ANRS 171 SYNACTHIV trial is an international multicenter pilot open label phase I trial. This trial will evaluate new procedures in LRA administration in 3 successive cohorts. In case of grade 3 to grade 5 adverse events, the inclusions and treatments will be (but not in a definitive manner) discontinued until the DSMB will conclude that the event was unrelated. Enrolment in cohort 2 then in cohort 3 will start only if no clinical grade 3 to grade 5 adverse event related to the LRAs occurs in the previous cohort.

Phase:

Phase 1

Details

Lead Sponsor:

ANRS, Emerging Infectious Diseases

Collaborator:

INSERM SC10-US19

Treatments:

Decitabine
Romidepsin